A new class of antifungal drugs to treat resistant fungal infections.
Background:
Fungal Infections are a major cause of human disease. Annually, over 150 million severe cases of fungal infections occur worldwide, resulting in approximately 1.7 million deaths per year.The four classes of antifungal drugs to treat life-threatening infections have limitations, including toxicity, drug-drug interactions, inconvenient dosing, and increasing incidence of resistance. There is an urgent need to discover and develop the next generation of antifungal drugs.
Technology Overview:
This technology developed by researchers at SUNY Upstate Medical University consists of a new molecular target, Ess1 for inhibition as a potential treatment for fungal infections, including those resistant to currently used antifungal drugs. The novel molecular target of this method is a highly conserved fungal enzyme essential for growth and virulence of various fungal species, including Saccharomyces cerevisiae, Candida albicans, and Cryptococcus neoformans. Thus, the technology promises broad-spectrum activity against various pathogenic fungi.
http://suny.technologypublisher.com/files/sites/110-21001.jpg
https://unsplash.com/photos/Wk902ZLaA7M
Advantages:
Treatment of antimycotic-resistant infections.
Broad-spectrum activity.
Applications:
Fungal infections
Stage of Development:
Molecular Targets Found